Report Library
All Reports
Q4 2015 Outlook Report
October 09, 2015
In this quarter's report, we cover catalysts from 22 drugs, devices and diagnostics. We have also included a list of Large Impact catalysts in
the drug and device/diagnostic areas through Q4 2015 from our sister product, CatalystTracker. In addition, each drug’s likelihood of
Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are
provided.
Our Q3 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 75% of catalyst outcomes that occurred in Q3 2015.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.
For our disclosures, please read the BioMedTracker Research Standards.
Our Q3 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 75% of catalyst outcomes that occurred in Q3 2015.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: |
Anesthesia
Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)) Breast Cancer Chronic Pain Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI) Community Acquired Pneumonia (CAP) (Antibacterial) Coronary Artery Disease Drug Toxicity Dry Eye (Ophthalmology) Gout Graft vs. Host Disease (GVHD) - Treatment Hyperkalemia Hypogonadism Migraine and Other Headaches Muscular Dystrophy - Unspecified Pancreatic Cancer Rheumatoid Arthritis (RA) |
Additional Resources: